How does stem cell therapy treat ulcerative colitis?

MSCs modulate the overactive immune response driving UC, promote mucosal healing in the colon, reduce intestinal inflammation, and help restore the gut barrier function. This can reduce flare frequency and severity.

Can stem cell therapy achieve remission in ulcerative colitis?

MSC therapy has helped many UC patients achieve clinical remission or significant symptom reduction. Studies show improvements in endoscopic scores, reduced inflammation markers, and improved quality of life.

What UC symptoms improve with stem cell therapy?

Patients commonly report reduced abdominal pain, decreased bloody diarrhea, improved stool consistency, reduced urgency, better appetite, and increased energy levels within 1-3 months of treatment.

Stem Cells for Crohn's Disease: A Breakthrough in IBD Treatment

How stem cell therapy is transforming Crohn's disease treatment. MSC therapy for fistulas, HSCT for severe Crohn's, Darvadstrocel, and regenerative IBD treatment.

Why Crohn's Disease Responds to MSC Therapy

Crohn's disease is a transmural inflammatory bowel condition driven by dysregulated Th1/Th17 immune responses against intestinal bacteria. TNF-α, IL-12, and IL-23 orchestrate the chronic intestinal inflammation causing mucosal ulceration, strictures, and fistulae. MSCs suppress Th17 expansion, promote T-regulatory cell activity, reduce pro-inflammatory cytokines, and directly promote intestinal mucosal healing through secretion of EGF, KGF, and HGF. Critically, Alofisel® (darvadstrocel — expanded adipose MSCs) became the first EU-approved MSC therapy product in 2018 for complex perianal fistulae in Crohn's disease, providing regulatory validation for the mechanism.

What Results Can Crohn's Patients Expect?

For luminal Crohn's disease, published studies report clinical remission rates of 40–60% at 12 months, with endoscopic healing in 30–45% of patients. Fistulating disease (perianal fistulae) shows even stronger evidence, with 50–65% combined remission rates in the pivotal ADMIRE-CD trial that supported Alofisel® approval. Patients failing anti-TNF biologics (infliximab, adalimumab) or with intolerance to conventional therapy represent the strongest candidates for MSC therapy as a next-line option.

Crohn's Treatment Protocol in Istanbul

StemCell Longevita's Crohn's programme combines systemic IV MSC infusion with targeted intestinal delivery as indicated. Pre-treatment evaluation includes CDAI assessment, colonoscopy/MRI enterography review, and inflammatory biomarker panel (CRP, faecal calprotectin, albumin). Post-treatment follow-up at 3, 6, and 12 months includes CDAI reassessment and endoscopic/radiological evaluation coordinated with the patient's gastroenterologist.

Frequently Asked Questions

How does stem cell therapy treat ulcerative colitis?: MSCs modulate the overactive immune response driving UC, promote mucosal healing in the colon, reduce intestinal inflammation, and help restore the gut barrier function. This can reduce flare frequency and severity.
Can stem cell therapy achieve remission in ulcerative colitis?: MSC therapy has helped many UC patients achieve clinical remission or significant symptom reduction. Studies show improvements in endoscopic scores, reduced inflammation markers, and improved quality of life.
What UC symptoms improve with stem cell therapy?: Patients commonly report reduced abdominal pain, decreased bloody diarrhea, improved stool consistency, reduced urgency, better appetite, and increased energy levels within 1-3 months of treatment.

Stem Cells for Crohn's Disease: A Breakthrough in IBD Treatment

Why Crohn's Disease Responds to MSC Therapy

What Results Can Crohn's Patients Expect?

Crohn's Treatment Protocol in Istanbul

Frequently Asked Questions

Transform Your Health with Regenerative Medicine in Istanbul